Case Study

A novel non-Invasive in vivo tool for the assessment of NASH

in-vivo-diagnostic-tool-512

Non-alcoholic fatty liver disease (NAFLD) describes a progressive pathology that affects the liver. Fat accumulation causes fatty liver (NAFL) or steatosis to develop, which leads to lipotoxicity and in turn induces liver inflammation and apoptosis, resulting in non-alcoholic steatohepatitis (NASH). NASH can progress to fibrosis and then cirrhosis, which in some cases will lead to hepatocellular carcinoma (HCC).

Read this case study to learn how non-invasive preclinical in vivo imaging was used to longitudinally visualize and quantify NASH with the goal of investigating the efficacy of liver fibrosis-preventing drugs on NAFLD progression.

For research use only. Not for use in diagnostic procedures. 

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

A novel non-Invasive in vivo tool for the assessment of NASH

Download Case Study